| HER2 as a prognostic marker in gastric cancer-a systematic analysis of data from the literature JT Jørgensen, M Hersom Journal of Cancer 3, 137, 2012 | 322 | 2012 |
| Targeted HER2 treatment in advanced gastric cancer JT Jørgensen Oncology 78 (1), 26-33, 2010 | 240 | 2010 |
| The value of TOP2A gene copy number variation as a biomarker in breast cancer: Update of DBCG trial 89D K Vang Nielsen, B Ejlertsen, S Møller, J Trøst Jørgensen, A Knoop, ... Acta oncologica 47 (4), 725-734, 2008 | 150 | 2008 |
| Digital X‐ray radiogrammetry: a new appendicular bone densitometric method with high precision JT Jørgensen, PB Andersen, A Rosholm, NH Bjarnason Clinical Physiology 20 (5), 330-335, 2000 | 128 | 2000 |
| Pain assessment of subcutaneous injections JT Jørgensen, J Rømsing, M Rasmussen, J Møller-Sonnergaard, L Vang, ... Annals of Pharmacotherapy 30 (7-8), 729-732, 1996 | 108 | 1996 |
| Companion diagnostics for targeted cancer drugs–clinical and regulatory aspects D Olsen, JT Jørgensen Frontiers in oncology 4, 105, 2014 | 100 | 2014 |
| Companion and complementary diagnostics–focus on PD-L1 expression assays for PD-1/PD-L1 checkpoint inhibitors in non–small cell lung Cancer M Hersom, JT Jørgensen Therapeutic drug monitoring 40 (1), 9-16, 2018 | 88 | 2018 |
| A normative reference database study for Pronosco X-posure System™ DM Black, L Palermo, T Sørensen, JT Jørgensen, C Lewis, F Tylavsky, ... Journal of clinical densitometry 4 (1), 5-12, 2001 | 80 | 2001 |
| Companion diagnostics—a tool to improve pharmacotherapy JT Jørgensen, M Hersom Annals of translational medicine 4 (24), 2016 | 70 | 2016 |
| A challenging drug development process in the era of personalized medicine JT Jørgensen Drug discovery today 16 (19-20), 891-897, 2011 | 69 | 2011 |
| Twenty years with personalized medicine: past, present, and future of individualized pharmacotherapy JT Jørgensen The oncologist 24 (7), e432-e440, 2019 | 68 | 2019 |
| Role of human epidermal growth factor receptor 2 in gastric cancer: biological and pharmacological aspects JT Jørgensen World Journal of Gastroenterology: WJG 20 (16), 4526, 2014 | 67 | 2014 |
| Companion diagnostics: the key to personalized medicine JT Jørgensen Expert Rev. Mol. Diagn 15 (2), 153-156, 2015 | 66 | 2015 |
| Companion diagnostic assays for PD-1/PD-L1 checkpoint inhibitors in NSCLC JT Jørgensen Expert review of molecular diagnostics 16 (2), 131-133, 2016 | 65 | 2016 |
| Pharmacodiagnostics and targeted therapies—a rational approach for individualizing medical anticancer therapy in breast cancer JT Jørgensen, KV Nielsen, B Ejlertsen The Oncologist 12 (4), 397-405, 2007 | 63 | 2007 |
| New Era of Personalized Medicine: A 10‐Year Anniversary JT Jørgensen The Oncologist 14 (5), 557-558, 2009 | 61 | 2009 |
| Companion and complementary diagnostics: clinical and regulatory perspectives JT Jørgensen Trends in cancer 2 (12), 706-712, 2016 | 52 | 2016 |
| From Blockbuster Medicine to Personalized Medicine JT Jørgensen Personalized Medicine 5 (1), 55-63, 2008 | 45 | 2008 |
| Response of cortical bone to antiresorptive treatment LHJT Jørgensen, TK Sørensen, L Baeksgaard Calcif Tissue Int 68, 135-139, 2001 | 44 | 2001 |
| The current landscape of the FDA approved companion diagnostics JT Jørgensen Translational Oncology 14 (6), 101063, 2021 | 42 | 2021 |
Bent EjlertsenDBCG在 rh.dk 的电子邮件经过验证
